These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing. Wilson RD; De Bie I; Armour CM; Brown RN; Campagnolo C; Carroll JC; Okun N; Nelson T; Zwingerman R; Audibert F; Brock JA; Brown RN; Campagnolo C; Carroll JC; De Bie I; Johnson JA; Okun N; Pastruck M; Vallée-Pouliot K; Wilson RD; Zwingerman R; Armour C; Chitayat D; De Bie I; Fernandez S; Kim R; Lavoie J; Leonard N; Nelson T; Taylor S; Van Allen M; Van Karnebeek C J Obstet Gynaecol Can; 2016 Aug; 38(8):742-762.e3. PubMed ID: 27638987 [TBL] [Abstract][Full Text] [Related]
27. Use of cell-free fetal DNA in maternal plasma for noninvasive prenatal screening. Wagner AJ; Mitchell ME; Tomita-Mitchell A Clin Perinatol; 2014 Dec; 41(4):957-66. PubMed ID: 25459783 [TBL] [Abstract][Full Text] [Related]
28. Prenatal diagnosis by chromosomal microarray analysis. Levy B; Wapner R Fertil Steril; 2018 Feb; 109(2):201-212. PubMed ID: 29447663 [TBL] [Abstract][Full Text] [Related]
29. Prenatal Diagnosis Procedures and Techniques to Obtain a Diagnostic Fetal Specimen or Tissue: Maternal and Fetal Risks and Benefits. Wilson RD; Gagnon A; Audibert F; Campagnolo C; Carroll J; J Obstet Gynaecol Can; 2015 Jul; 37(7):656-668. PubMed ID: 26366824 [TBL] [Abstract][Full Text] [Related]
30. Why do patients decline amniocentesis? Analysis of factors influencing the decision to refuse invasive prenatal testing. Sadlecki P; Grabiec M; Walentowicz P; Walentowicz-Sadlecka M BMC Pregnancy Childbirth; 2018 May; 18(1):174. PubMed ID: 29769050 [TBL] [Abstract][Full Text] [Related]
31. Committee Opinion No. 581: the use of chromosomal microarray analysis in prenatal diagnosis. American College of Obstetricians and Gynecologists Committee on Genetics Obstet Gynecol; 2013 Dec; 122(6):1374-7. PubMed ID: 24264715 [TBL] [Abstract][Full Text] [Related]
32. Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities. Norton ME; Baer RJ; Wapner RJ; Kuppermann M; Jelliffe-Pawlowski LL; Currier RJ Am J Obstet Gynecol; 2016 Jun; 214(6):727.e1-6. PubMed ID: 26709085 [TBL] [Abstract][Full Text] [Related]
33. How to choose a test for prenatal genetic diagnosis: a practical overview. Sparks TN; Dugoff L Am J Obstet Gynecol; 2023 Feb; 228(2):178-186. PubMed ID: 36029833 [TBL] [Abstract][Full Text] [Related]
34. Chromosomal abnormalities not currently detected by cell-free fetal DNA: a retrospective analysis at a single center. Shani H; Goldwaser T; Keating J; Klugman S Am J Obstet Gynecol; 2016 Jun; 214(6):729.e1-729.e11. PubMed ID: 26721783 [TBL] [Abstract][Full Text] [Related]
35. [The scope of prenatal diagnostic testing for chromosomal aberrations: broad or narrow? Ethical considerations on the choice of tests]. de Jong A; Dondorp WJ; de Wert GM Ned Tijdschr Geneeskd; 2009; 153():A1060. PubMed ID: 20015413 [TBL] [Abstract][Full Text] [Related]